Role of tumor necrosis factor-α in the human systemic endotoxin-induced transcriptome

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Scicluna, Brendon P ^a   Van't Veer, Cornelis ^a   Nieuwdorp, Max ^a   Felsmann, Karen ^b   Wlotzka, Britta ^b   Stroes, Erik S G ^a   Van Der Poll, Tom ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

^b SIRS Lab GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIPOPOLYSACCHARIDE; PLACEBO; TRANSCRIPTOME; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CAUCASIAN; DISEASE MODEL; DNA MODIFICATION; ENDOTOXEMIA; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IMMUNE RESPONSE; INFLAMMATION; LEUKOCYTE COUNT; MALE; NORMAL HUMAN; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; TRANSCRIPTION ELONGATION; TRANSCRIPTION INITIATION; TRANSCRIPTION REGULATION;

EPIGENESIS, GENETIC; GENE REGULATORY NETWORKS; HUMANS; LEUKOCYTE COUNT; LIPOPOLYSACCHARIDES; MALE; MOLECULAR SEQUENCE ANNOTATION; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TRANSCRIPTOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84893178246     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079051     Document Type: Article

References (50)

1. Aggarwal BB (2003) Signalling pathways of the TNF superfamily: a double-edged sword. Nat Rev Immunology 3: 745-756.
2. Parameswaran N, Patial S (2010) Tumor necrosis factor-α signaling in macrophages. Crit Rev Eukaryot Gene Expr 20: 87-103.
3. Bradley JR (2008) TNF-mediated inflammatory disease. J Pathol. 214: 149-160.
4. Reinhart K, Karzai W (2001) Anti-tumor necrosis factor therapy in sepsis: update on clinical trials and lessons learned. Crit Care Med. 29: S121-125. (Pubitemid 32681594)
5. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, et al. (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295: 2275-2285. (Pubitemid 43736578)
6. Winthrop KL (2006) Risk and prevention of tuberculosis and other serious opportunistic infections associated with the inhibition of tumor necrosis factor. Nat Clin Pract Rheumatol 2: 602-610.
7. Lorente JA, Marshall JC (2005) Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock 24 Suppl 1:107-119.
8. van der Poll T, Opal SM (2008) Host-pathogen interactions in sepsis. Lancet Infect Dis. 8: 32-43.
9. Calvano SE, Xiao W, Richards DR, Felciano RM, Baker HV, et al. (2005) A network-based analysis of systemic inflammation in humans. Nature 437: 1032-1037. (Pubitemid 41486985)
10. Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, et al. (2011) A genomic storm in critically injured humans. J Exp Med. 208: 2581-2590.
11. Seok J, Warren HS, Cuenca AG, Mindrinos MN, Baker HV, et al. (2013) Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 110:3507-12.
12. Nieuwdorp M, Meuwese MC, Mooij HL, van Lieshout MH, Hayden A, et al. (2009) Tumor necrosis factor-alpha inhibition protects against endotoxin-induced endothelial glycocalyx perturbation. Atherosclerosis 202: 296-303.
13. Troyanskaya O, Cantor M, Sherlock G, Brown P, Hastie T, et al. (2001) Missing value estimation methods for DNA microarrays. Bioinformatics 17: 520-525. (Pubitemid 32600498)
14. Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. Bioinformatics 24: 1547-1548. (Pubitemid 351911712)
15. Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, et al. (2004) Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 5: R80.
16. Buness A, Huber W, Steiner K, Sültmann H, Poustka A (2005) arrayMagic: two-colour cDNA microarray quality control and preprocessing. Bioinformatics 21: 554-556. (Pubitemid 40310247)
17. Huber W, von Heydebreck A, Sültmann H, Poustka A, Vingron M (2002) Variance stabilization applied to microarray data calibration and to the quantification of differential expression. Bioinformatics 18 Suppl 1: S96-104.
18. Langfelder P, Horvath S (2008) WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 9: 559.
19. Langfelder P, Zhang B, Horvath S (2008) Defining clusters from a hierarchical cluster tree: the Dynamic Tree Cut package for R. Bioinformatics 24: 719-720. (Pubitemid 351321220)
20. Ravasz E, Somera AL, Mongru DA, Oltvai ZN, Barabási AL (2002) Hierarchical organization of modularity in metabolic networks. Science 297: 1551-1555. (Pubitemid 34971002)
21. Barabási AL, Gulbahce N, Loscalzo J (2011) Network medicine: a network-based approach to human disease. Nat Rev Genet. 12: 56-68.
22. Horvath S, Dong J (2008) Geometric interpretation of gene coexpression network analysis. PLoS Comput Biol. 4: e1000117.
23. Shannon P, Markiel A, Ozier O, Baliga NS, Wang JT, et al. (2003) Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 13: 2498-2504. (Pubitemid 37428274)
24. Chen J, Bardes EE, Aronow BJ, Jegga AG (2009) ToppGene Suite for gene list enrichment analysis and candidate gene prioritization. Nucleic Acids Res. 37: W305-311.
25. Zhang B, Horvath S (2005) A general framework for weighted gene coexpression network analysis. Stat Appl Genet Mol Biol. 4: Article17.
26. Zhao W, Langfelder P, Fuller T, Dong J, Li A, et al. (2010) Weighted gene coexpression network analysis: state of the art. J Biopharm Stat. 20: 281-300.
27. Heng TS, Painter MW, Immunological Genome Project Consortium (2008) The Immunological Genome Project: networks of gene expression in immune cells. Nat Immunol. 9: 1091-1094.
28. Kadonaga JT (2004) Regulation of RNA polymerase II transcription by sequence-specific DNA binding factors. Cell. 116: 247-257.
29. Kouzarides T (2007) Chromatin modifications and their function. Cell. 128: 693-705.
30. Hargreaves DC, Horng T, Medzhitov R (2009) Control of inducible gene expression by signal-dependent transcriptional elongation. Cell. 138:129-45.
31. Suffredini AF, Reda D, Banks SM, Tropea M, Agosti JM, et al. (1995) Effects of recombinant dimeric TNF receptor on human inflammatory responses following intravenous endotoxin administration. J Immunol. 155:5038-5045.
32. van der Poll T, Coyle SM, Levi M, Jansen PM, Dentener M, et al. (1997) Effect of a recombinant dimeric tumor necrosis factor receptor on inflammatory responses to intravenous endotoxin in normal humans. Blood. 89:3727-3734. (Pubitemid 27227096)
33. Horvath S, Zhang B, Carlson M, Lu KV, Zhu S, et al. (2006) Analysis of oncogenic signaling networks in glioblastoma identifies ASPM as a molecular target. Proc Natl Acad Sci USA. 103: 17402-17407. (Pubitemid 44788981)
34. Brealey D, Brand M, Hargreaves I, Heales S, Land J, et al. (2002) Association between mitochondrial dysfunction and severity and outcome of septic shock. Lancet 360: 219-223. (Pubitemid 34804650)
35. Sarrias MR, Grønlund J, Padilla O, Madsen J, Holmskov U, et al. (2004) The Scavenger Receptor Cysteine-Rich (SRCR) domain: an ancient and highly conserved protein module of the innate immune system. Crit Rev Immunol. 24: 1-37. (Pubitemid 39655010)
36. Sarrias MR, Farnós M, Mota R, Sánchez-Barbero F, Ibáñez A, Gimferrer I, et al. (2007) CD6 binds to pathogen-associated molecular patterns and protects from LPS-induced septic shock. Proc Natl Acad Sci USA. 104: 11724-11729. (Pubitemid 47175080)
37. Stearns-Kurosawa DJ, Osuchowski MF, Valentine C, Kurosawa S, Remick DG (2011) The pathogenesis of sepsis. Annu Rev Pathol. 6: 19-48.
38. Hotchkiss RS, Monneret G, Payen D (2013) Immunosuppression in sepsis: a novel understanding of the disorder and a new therapeutic approach. Lancet Infect Dis. 13: 260-268.
39. Grimm S, Baeuerle PA (1993) The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits. Biochem J. 290: 297-308. (Pubitemid 23094919)
40. Kobayashi K, Hernandez LD, Galán JE, Janeway CA Jr, Medzhitov R, et al. (2002) IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202. (Pubitemid 34876547)
41. Yoza BK, Hu JY, Cousart SL, Forrest LM, McCall CE (2006) Induction of RelB participates in endotoxin tolerance. J Immunol. 177: 4080-4085. (Pubitemid 44359942)
42. van't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, et al. (2007) Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endotoxemia model. J Immunol. 179: 7110-7120.
43. Cavaillon JM, Adib-Conquy M (2006) Bench-to-bedside review: endotoxin tolerance as a model of leukocyte reprogramming in sepsis. Crit Care. 10: 233.
44. Broad A, Jones DE, Kirby JA (2006) Toll-like receptor (TLR) response tolerance: a key physiological "damage limitation" effect and an important potential opportunity for therapy. Curr Med Chem. 13: 2487-2502. (Pubitemid 44364151)
45. Maekawa T, Sakura H, Sudo T, Ishii S (1989) Putative metal finger structure of the human immunodeficiency virus type 1 enhancer binding protein HIV-EP1. J Biol Chem. 264: 14591-14593. (Pubitemid 19237266)
46. Medzhitov R, Horng T (2009) Transcriptional control of the inflammatory response. Nat Rev Immunol. 9: 692-703.
47. Nicodeme E, Jeffrey KL, Schaefer U, Beinke S, Dewell S, et al. (2010) Suppression of inflammation by a synthetic histone mimic. Nature. 468:1119-1123.
48. Khor CC, Vannberg FO, Chapman SJ, Guo H, Wong SH, et al. (2010) CISH and susceptibility to infectious diseases. N Engl J Med. 362: 2092-2101.
49. Wong HR, Cvijanovich NZ, Hall M, Allen GL, Thomas NJ, et al. (2012) Interleukin-27 is a novel candidate diagnostic biomarker for bacterial infection in critically ill children. Crit Care. 16: R213.
50. Wirtz S, Tubbe I, Galle PR, Schild HJ, Birkenbach M, et al. (2006) Protection from lethal septic peritonitis by neutralizing the biological function of interleukin 27. J Exp Med. 203: 1875-1881. (Pubitemid 44188462)